NR4A1 and breast cancer: ODX is a genomic test that predicts the likelihood of chemotherapy benefit [5] and the 10-year risk of distant recurrence [8,9] for early-stage BC (ESBC) women with hormone receptors positive/human epidermal growth factor 2—neu negative (HR+/HER2-).